IACS-6274 Shows Promise in Ovarian Cancer Trial

European Organisation for Research and Treatment of Cancer

Barcelona, Spain: Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment with a drug called IACS-6274 when combined with the targeted therapy bevacizumab and paclitaxel chemotherapy.

Results from a phase I clinical trial in 14 patients, presented on Thursday at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, showed the combination was safe, and that nine out of 13 patients (69%) with tumours that could be measured during scans had confirmed partial responses in which the tumours shrank by at least 30%. Three patients had stable disease, in which the cancer neither grew nor shrank. One patient had early clinical progression of their disease so there were no further scans to re-stage the tumour, and they left the trial.

Twelve weeks after treatment started, cancer remained under control for 11 out of 13 patients (85%), and the duration of treatments lasted beyond 37 months in a subset of patients.

The trial was led by Timothy Yap, professor of Investigational Cancer Therapeutics and vice president and head of clinical development in the Therapeutics Discovery division at The University of Texas MD Anderson Cancer Center, USA, where IACS-6274 was invented and where the trial was conducted.

He said: "We observed deep and very durable responses in patients with advanced, hard-to-treat ovarian cancer. Patients also reported an improvement in their cancer-related symptoms. In ten out of 13 patients (77%) with radiological measurable disease, we observed durable tumour regression with partial responses or stable disease lasting four months or more."

Only about 15% of women diagnosed with advanced ovarian cancer will survive for at least five years and often they will have received several different anti-cancer therapies to treat it.

Prof. Yap said: "Ovarian cancer often adapts to approved standard-of-care anti-cancer therapies, such as bevacizumab and chemotherapy, by switching its diet to rely heavily on a nutrient called glutamine to survive and grow. In this way, the cancer becomes resistant to treatments. We have carried out research in the laboratory that showed that blocking this glutamine pathway with a glutaminase-1 (GLS1) inhibitor drug successfully shrank these resistant tumours, especially when combined with bevacizumab and chemotherapy.

"These promising results provided the rationale to design and conduct a clinical trial to test the safety, tolerability and preliminary anti-tumour activity of the GLS1 inhibitor, IACS-6274, in combination with bevacizumab and paclitaxel chemotherapy in patients whose ovarian cancers have stopped responding to standard treatment."

A total of 14 patients with advanced ovarian cancer and with an average age of 56 years (range 45-75 years), received 120 mg or 180 mg of IACS-6274 orally, twice a day throughout the trial, together with bevacizumab (10 mg/Kg on days one and 15) and paclitaxel chemotherapy (80 mg/m2 on days one, eight and 15) given intravenously in 21-day cycles. Tumours in 13 out of 14 patients (93%) had failed to respond to platinum-based therapies.

The researchers also took tumour and blood samples to analyse them for an enzyme called ASNS, as well as changes to genes and various cell communication pathways.

"Some cancers lack a specific enzyme called ASNS, which leaves them with only one backup supply line for the nutrients they need to survive. The GLS1 inhibitor, IACS-6274, works by blocking that exact backup supply line, essentially starving and destroying the tumour cells while leaving healthy cells unharmed," said Prof. Yap. "In this group of patients, eight out of 14 (57%) had ASNS loss."

Both dose levels were well-tolerated. Common, mild, adverse side effects included nausea, fatigue, hair loss, anaemia, nose bleeds, elevated levels of the enzymes ALT/AST that indicate the liver is under stress, reduced white blood cell count (neutropenia), nail disorders and vision disturbances (photopsia). More serious side effects, which were treated successfully, included neutropenia, elevated blood pressure and anaemia. No patients suffered any side effects that limited the level of the treatment dose.

"Analysis of the tumour and blood samples in the laboratory showed that the treatment also reshaped the tumour microenvironment toward greater activation of the immune system, while ASNS loss was associated with a high response rate, providing a potential predictive biomarker of response to the drug combination, which we will study further in the clinic. Notably, six out of the eight patients with tumours lacking ASNS achieved radiological partial responses," said Prof. Yap.

The analyses also revealed another way that cancer cells can become resistant to treatment and start to spread around the body, a process called epithelial-to-mesenchymal transition (EMT).

"Our findings suggest that tumours undergoing an EMT-like transition may adapt to GLS1 inhibition by activating the ASNS pathway as an alternative metabolic survival mechanism. If validated, this could provide the rationale for combining GLS1 inhibition with strategies targeting this compensatory pathway to prevent or overcome resistance," said Prof. Yap.

The researchers have started to treat an increased number of patients with advanced ovarian cancer. A further 15 patients will be treated, followed by another 15 patients if the treatment continues to be effective.

Strengths of the trial include the fact that researchers are collecting tumour and blood samples throughout the duration of the study, so that they can conduct 'reverse translational studies' in the laboratory to understand why some patients respond to the treatment while others do not. A limitation is that only a small number of patients have been treated so far in order to achieve early, proof-of-concept for the drug combination and to support the two-stage expansion phase of the trial.

Professor Elena Garralda, chair of the EORTC-NCI-AACR Symposium and co-director of the Vall d'Hebron Institute of Oncology's clinical research programme, was not involved with the study. She commented: "Advanced ovarian cancer is very hard to treat successfully, so the results from this phase I clinical trial of IACS-6274, in combination with two existing therapies for the disease, are encouraging. These results are especially significant as the patients had received several other previous treatments and their tumours had not responded to them. We look forward to results from the expanded phase I trial and, if these are promising, to IACS-6274 being taken forward into phase II and III clinical trials.

"This research is also a very good example of how work carried out in the laboratory can translate to potentially better treatments for patients, with the clinical results taken back to the lab to be investigated further – a process of 'reverse translation' that help us understand the biological mechanisms underpinning the cancer and its response to targeted drugs."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.